Cancer is a leading problem in the USA and throughout the world. The American Cancer Society estimates that there will be almost 1.4 million new cases of cancer diagnosed in the USA in 2004 and almost 564,000 deaths.1 It is the second leading cause of death in the USA, accounting for approximately 23% of all deaths behind heart diseases which account for 29%.


Prostate Cancer Radical Prostatectomy Follicular Lymphoma Lynch Syndrome Radical Cystectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A et al. Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians 2004; 54(1): 8–29.Google Scholar
  2. 2.
    Geraci MW. Practical Cancer Genetics, Genomics and Proteomics. Presentation AAIM Annual Scientific Program, Denver, CO, October 5, 2004.Google Scholar
  3. 3.
    Ma PC, Carbone D. Overview of gene expression profiling and proteomics in clinical oncology. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  4. 4.
    Umar A et al. Testing guidelines for hereditary non-polyposis colorectal cancer. Nature Reviews/Cancer 2004; 4: 153–8.Google Scholar
  5. 5.
    Savage DG, Antman KH. Imatinib Mesylate — A New Oral Targeted Therapy. N Engl J Med 2002; 346: 683–93.CrossRefGoogle Scholar
  6. 6.
    Harris NL et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5): 1361–92.Google Scholar
  7. 7.
    Falini B, Mason DY. Proteins encoded by genes involved in chromosomal aalterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409–426.CrossRefGoogle Scholar
  8. 8.
    Harris NL et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting — Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12): 3835–49.Google Scholar
  9. 9.
    Greene FL et al. AJCC Cancer Staging Manual. 6th edn. New York: Springer-Verlag, 2002.CrossRefGoogle Scholar
  10. 10.
    Zimmerman SE. Oncology. In: Medical Selection of Life Risks, 4 edn. Brackenridge et al. (eds). London: MacMillan Reference LTD, 1998.Google Scholar
  11. 11.
    Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 1. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992; 339: 1–15.Google Scholar
  12. 12.
    Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 2. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992; 339: 71–85.Google Scholar
  13. 13.
    Holland JF et al. Principles of medical oncology. In: Cancer Medicine e. 5. Bast RC et al (eds). 5th edn. Hamilton, ON: B. C. Decker, Inc., 2000.Google Scholar
  14. 14.
    Forastiere A, Koch W, Trotti A, Sidransky D. Head and Neck Cancer. N Engl J Med 2001; 345: 1890–1900.CrossRefGoogle Scholar
  15. 15.
    Brunning RD et al. Acute myeloid leukaemias and myelodysplastic syndromes, therapy related. In Jaffe ES et al. (eds). World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2001.Google Scholar
  16. 16.
    Ng AK et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100(6): 1989–96.CrossRefGoogle Scholar
  17. 17.
    Ng AK et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 2002; 20(8): 2101–8.CrossRefGoogle Scholar
  18. 18.
    van Leeuwen FE et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994; 12(2): 312–25.Google Scholar
  19. 19.
    Swerdlow AJ et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18(3): 498–509.Google Scholar
  20. 20.
    Dores GM et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20(16): 3484–94.CrossRefGoogle Scholar
  21. 22.
    Mauch PM et al. Second malignancies after treatment for laparotomy staged IA–IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood 1996; 87(9): 3625–32.Google Scholar
  22. 23.
    Hoppe RT. Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol 1997; 8(Suppl 1): 115–8.CrossRefGoogle Scholar
  23. 24.
    Henry-Amar M. Second cancer after the treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s Disease. Ann Oncol 1992; 3 (Suppl 4): 117–28.CrossRefGoogle Scholar
  24. 25.
    Michaelson MD, Oh WK. Serum tumor markers in testicular cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  25. 26.
    Russell HV, Shohet JM, Nuchtern JG. Treatment and prognosis of neuroblastoma. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  26. 27.
    Hayes DF. Measurement of prognostic factors in breast cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  27. 28.
    Weir HK et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. JNCI 2003; 95(17): 1276–99.CrossRefGoogle Scholar
  28. 29.
    Schwartz GF et al. The Consensus Conference Committee. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25. 1999. Cancer 2000; 88: 946–54.CrossRefGoogle Scholar
  29. 30.
    Pharoah PDP et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71: 800–9.CrossRefGoogle Scholar
  30. 31.
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995; 56: 265–71.CrossRefGoogle Scholar
  31. 32.
    Isaacs C, Fletcher SW, Peshkin BN. Genetic testing for breast cancer. In: Rose BD (ed). UpToDate, Waltham, MA, 2001–2005 ( Scholar
  32. 33.
    Marcus JN et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697–709.CrossRefGoogle Scholar
  33. 34.
    Johannsson OT et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362–71.CrossRefGoogle Scholar
  34. 35.
    Peshkin BN, Isaacs C. Risk assessment in women with an inherited predisposition to breast cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  35. 36.
    Warner E et al. Surveillance of BRCAl and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292(11): 1317–25.CrossRefGoogle Scholar
  36. 37.
    Kriege M et al. Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. N Engl J Med 2004; 351(5): 427–37.CrossRefGoogle Scholar
  37. 38.
    Woodward WA et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003; 21: 3244–8.CrossRefGoogle Scholar
  38. 39.
    Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med 1995; 333: 1444–55.CrossRefGoogle Scholar
  39. 40.
    Savarese DMF, Hayes DF. Overview of breast cancer and treatment for early stage disease. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  40. 41.
    Harlow SP, Weaver DL. Management of the regional lymph nodes in breast cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  41. 42.
    Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group, Lancet 1998; 352: 930–42.CrossRefGoogle Scholar
  42. 43.
    Eifel P et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93(13): 979–89.CrossRefGoogle Scholar
  43. 44.
    O’Shaughnessy J. Adjuvant chemotherapy for early stage breast cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  44. 45.
    Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 351: 1451–67.CrossRefGoogle Scholar
  45. 46.
    Rosen PP et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0 and T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11(11): 2090–100.Google Scholar
  46. 47.
    Cancer Facts and Figures 2004. Atlanta: American Cancer Society, 2004.Google Scholar
  47. 48.
    Hankey BF et al. Cancer surveillance series: interpreting trends in prostate cancer — part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91(12): 1017–24.CrossRefGoogle Scholar
  48. 49.
    Miller DC et al. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003; 98(6): 1169–78.CrossRefGoogle Scholar
  49. 50.
    Thompson IM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349(3): 215–24. Epub 2003 Jun 24.CrossRefGoogle Scholar
  50. 51.
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2. 6 to 4. 0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277(18): 1452–5.CrossRefGoogle Scholar
  51. 52.
    Ravery V. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999; 17(3): 127–9.Google Scholar
  52. 53.
    Arming CL et al. TI — Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165(4): 1146–51.CrossRefGoogle Scholar
  53. 54.
    Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035.Google Scholar
  54. 55.
    Moul JW. Management of rising serum PSA following local therapy for prostate cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  55. 56.
    Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591–7.CrossRefGoogle Scholar
  56. 57.
    D’Amico AV et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95(18): 1376–83.CrossRefGoogle Scholar
  57. 58.
    Klein E. Early stage prostate cancer: Predicting the pathologic extent of disease. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  58. 59.
    Partin AW et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150(1): 110–4.Google Scholar
  59. 60.
    Partin AW et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58(6): 843–8.CrossRefGoogle Scholar
  60. 61.
    Grossfeld GD et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001; 165(3): 851–6.CrossRefGoogle Scholar
  61. 62.
    Shipley WU et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281(17): 1598–604.CrossRefGoogle Scholar
  62. 63.
    Amling CL et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164(1): 101–5.CrossRefGoogle Scholar
  63. 64.
    Holmberg L et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347(11): 781–9.CrossRefGoogle Scholar
  64. 65.
    Kupelian P et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1–2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997; 3(2): 78–87.Google Scholar
  65. 66.
    Kuban DA et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57(4): 915–28.CrossRefGoogle Scholar
  66. 67.
    D’Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280(11): 969–74.CrossRefGoogle Scholar
  67. 68.
    Ragde H et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998; 83(5): 989–1001.CrossRefGoogle Scholar
  68. 69.
    Ragde H et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000; 89(1): 135–41.CrossRefGoogle Scholar
  69. 70.
    Jani AB, Vogelzang N. Management of locally advanced prostate cancer (clinical stage T3) In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  70. 71.
    Lerner SE et al. Primary surgery for clinical stage T3 adenocarcinoma of the prostate. In: Comprehensive Textbook of Genitourinary Oncology, 2nd edn, Vogelzang NJ et al. (eds), Lippincott, Williams and Wilkins, Philadelphia, 2000; 793.Google Scholar
  71. 72.
    Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79(2): 235–46.CrossRefGoogle Scholar
  72. 73.
    Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S: an update of trends by gender, race, age, subsite, and stage, 1975–1994. Cancer 1999; 85: 1670–6.CrossRefGoogle Scholar
  73. 74.
    Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658–62.CrossRefGoogle Scholar
  74. 75.
    Matzakos T, Lawrence SP, Ahnen DJ. Epidemiology and risk factors for colorectal cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  75. 76.
    Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 1995; 46: 371–9.CrossRefGoogle Scholar
  76. 77.
    Lynch HT et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104: 1535–49.Google Scholar
  77. 78.
    Lynch JP, Hoops TC. The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am 2002; 16: 775–810.CrossRefGoogle Scholar
  78. 79.
    Nelson H et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93: 583–96.CrossRefGoogle Scholar
  79. 80.
    Weeks JC et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002; 287: 321–8.CrossRefGoogle Scholar
  80. 81.
    Conte CC et al. Management of endoscopically removed malignant colon polyps. J Surg Oncol 1987; 36: 116–21.CrossRefGoogle Scholar
  81. 82.
    Haggitt RC et al. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985; 89: 328–36.Google Scholar
  82. 83.
    Wilcox GM, Anderson PB, Colacchio TA. Early invasive carcinoma in colonic polyps. A review of the literature with emphasis on the assessment of the risk of metastasis. Cancer 1986; 57: 160–71.CrossRefGoogle Scholar
  83. 84.
    Compton CC et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979–94.Google Scholar
  84. 85.
    Cohen AM et al. Prognosis of node-positive colon cancer. Cancer 1991; 67: 1859–61.CrossRefGoogle Scholar
  85. 86.
    Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985–95. Cancer 1998; 83: 2408–18.CrossRefGoogle Scholar
  86. 87.
    Chen L, Berek JS. Clinical manifestations, diagnosis, and staging of ovarian cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  87. 88.
    Morice P et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75(1): 92–6.CrossRefGoogle Scholar
  88. 89.
    Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002; 86 (1): 34–7.CrossRefGoogle Scholar
  89. 90.
    Zanetta G et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19 (10): 2658–64.Google Scholar
  90. 91.
    Bristow RE et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248–59.CrossRefGoogle Scholar
  91. 92.
    Hoskins WJ et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170(4): 974–80.CrossRefGoogle Scholar
  92. 93.
    Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69(2): 103–8.CrossRefGoogle Scholar
  93. 94.
    Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994 Dec; 55 (3 Pt 2):S91–6.CrossRefGoogle Scholar
  94. 95.
    Thigpen JT. Limited-stage ovarian carcinoma. Semin Oncol 1999; 26(6 Suppl 18): 29–33.Google Scholar
  95. 96.
    Morgan RJ Jr et al. NCCN Ovarian Cancer Practice Guidelines — The National Comprehensive Cancer Network. Oncology (Huntingt) 1996; 10(11 Suppl): 293–310.Google Scholar
  96. 97.
    Heintz APM et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6: 107–38.Google Scholar
  97. 98.
    MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14(4): 1282–90.Google Scholar
  98. 99.
    Wilder RB et al. Long-term results with radiotherapy for Stage I–II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51(5): 1219–27.CrossRefGoogle Scholar
  99. 100.
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long term follow-up of no initial therapy. J Clin Oncol 2004; 22(8): 1454–9. Epub 2004 Mar 15.CrossRefGoogle Scholar
  100. 101.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311(23): 1471–5.CrossRefGoogle Scholar
  101. 102.
    Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 1979; 90(1): 10–3.CrossRefGoogle Scholar
  102. 103.
    Baldini L et al. Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 2003; 21(8): 1459–65.CrossRefGoogle Scholar
  103. 104.
    Gallagher CJ et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4(10): 1470–80.Google Scholar
  104. 105.
    Johnson PW et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13(1): 140–7.Google Scholar
  105. 106.
    Solal-Celigny P et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1996; 14(2): 514–19.Google Scholar
  106. 107.
    Leonard JP et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003; 21(16): 3051–9.CrossRefGoogle Scholar
  107. 108.
    Mead GM et al. An international evaluation of CODOX-M and CODOX-M alternating with rVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13(8): 1264–74.CrossRefGoogle Scholar
  108. 109.
    Spina M et al. Burkitt’s lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer 1998; 82(4): 766–74.CrossRefGoogle Scholar
  109. 110.
    Magrath I et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14(3): 925–34.Google Scholar
  110. 111.
    Kantarjian HM et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18(3): 547–61.Google Scholar
  111. 112.
    A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14): 987–94.CrossRefGoogle Scholar
  112. 113.
    Solal-Celigny P et al. Follicular lymphoma international prognostic index. Blood 2004; 104(5): 1258–65.CrossRefGoogle Scholar
  113. 114.
    Armitage JO, Weisenburger DD. New approach to classifying Non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998; 16:2780–95.Google Scholar
  114. 115.
    Skinner DG et al. Cancer of the bladder. In: Adult and Pediatric Urology. 4th edn. Gillenwater et al. (eds) Philadelphia: Lippincott Williams & Wilkins; 2002: 1297–1362.Google Scholar
  115. 116.
    Cannon SB. Staging and Terminology of Superficial Urinary Bladder Tumors. Journal of Insurance Medicine 2001 33: 360–2.Google Scholar
  116. 117.
    Herr HW, Jaske G, Sheinfeld J. The T1 bladder tumor. Semin Urol 1990; 8: 254.Google Scholar
  117. 118.
    Soloway MS, Sofer M, Vaidya A. Contemporary Management of stage Tl trasnitional cell carcinoma of the bladder. J Urol 2002; 167: 1573.CrossRefGoogle Scholar
  118. 119.
    Smith JA et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuslce invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162: 1697–1701.CrossRefGoogle Scholar
  119. 120.
    Shahin O et al. A retrospective analysis of 153 patients treated with or without intravesical bacilus Calmette-Guerin for primary stage Tl grade 3 bladder cancer: recurrence, progression, and survival. J Urol 2003; 169: 96.CrossRefGoogle Scholar
  120. 121.
    Cheng L et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469–74.CrossRefGoogle Scholar
  121. 122.
    Hudson M, Herr H. Carcinoma in situ of the bladder. J Urol 1995; 153: 564–72.CrossRefGoogle Scholar
  122. 123.
    Dalbagni G, Herr H. Treatment of superficial bladder cancer. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  123. 124.
    Herr H, Lamm D, Denis L. Management of superficial bladder cancer. In: Raghavan D, Scher H, Leibel S and Lange P (editors). Principles and Practice of Genitourinary Oncology, Lippincott Raven, Philadephia, 1997; 273–280.Google Scholar
  124. 125.
    Stein J et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 10,545 patients. J Clin Oncol 2001; 9: 666–75.Google Scholar
  125. 126.
    Raghavan D. Bladder, Renal, and Testicular Cancer. In: ACP Medicine. Danbury, CT: WebMD Professional Publishing, 2003.Google Scholar
  126. 127.
    Rhodes AR et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987; 258(21): 3146–54.CrossRefGoogle Scholar
  127. 128.
    Balch CM et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635–48.Google Scholar
  128. 129.
    Balch CM et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19(16): 3622–34.Google Scholar
  129. 130.
    Shaw JC, Overview of melanoma. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  130. 131.
    Sober AJ et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579.CrossRefGoogle Scholar
  131. 132.
    Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch Dermatol 1997; 133(8): 1014–20.CrossRefGoogle Scholar
  132. 133.
    Schuchter L et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 1996; 125(5): 369–75.CrossRefGoogle Scholar
  133. 134.
    Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170(1): 5–11.CrossRefGoogle Scholar
  134. 135.
    Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337(4): 242–53.CrossRefGoogle Scholar
  135. 136.
    International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15(2): 594–603.Google Scholar
  136. 137.
    Warde P et al. Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 1995; 13: 2255–62.Google Scholar
  137. 138.
    Jones RH, Vasey PA Part II: Testicular cancer — management of advanced disease. The Lancet Oncology 2003; 4(12): 738–47.CrossRefGoogle Scholar
  138. 139.
    Toner GC, Motzer RJ. Poor prognosis germ-cell tumors — current status and future directions. Semin Oncol 1998; 25: 194–202.Google Scholar
  139. 140.
    Rose SR. Endocrine surveillance in childhood cancer survivors. In: UpToDate, Rose BD (ed), UpToDate, Wellesley, MA, 2004.Google Scholar
  140. 141.
    Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54: 208–36.CrossRefGoogle Scholar
  141. 142.
    Hawkins MM. Long-term Survivors of Childhood Cancers: What Knowledge Have We Gained? Nat Clin Pract Oncol 2004; 1(1): 26–31.CrossRefGoogle Scholar
  142. 143.
    Mertens AC et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 2001; 19: 3163–72.Google Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Limited 2006

Authors and Affiliations

  • Shanklin B. Cannon

There are no affiliations available

Personalised recommendations